Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Spermidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.93 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 5/20 | 0.93 |
| ▸ | CA6 | P23280 | 5/20 | 0.93 |
| ▸ | CA7 | P43166 | 5/20 | 0.93 |
| ▸ | CA9 | Q16790 | 5/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.93 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.93 |
| ▸ | CA4 | P22748 | 4/20 | 0.93 |
| ▸ | CA5A | P35218 | 4/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.93 |
| ▸ | CA3 | P07451 | 3/20 | 0.93 |
| ▸ | F13A1 | P00488 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | THPO | P40225 | 2/20 | 0.93 |
| ▸ | CA1 | P00915 | 2/20 | 0.93 |
| ▸ | UBE2N | P61088 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spermidine SCHEMBL3623585 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL7928492 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL573341 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL343877 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL29150448 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL9392489 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL31268131 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Spermidine SCHEMBL2514294 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL8186500 | 0.97 | LMNA (0.94) | LMNASMN1; SMN2CA12CA6CA7 | |
| Hydrochloric Acid SCHEMBL30866180 | 0.97 | LMNA (0.93) | LMNASMN1; SMN2CA12CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119219502-A | Preparation method of spermidine | 达高工业技术研究院(广州)有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-115876904-B | Method for detecting purity of spermidine hydrochloride and related substances thereof | 尚科生物医药（上海）有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-116693402-A | Spermidine hydrochloride crystal compound and preparation method thereof | 无锡富泽药业有限公司 | 2023-09-05 | — | — | CN | claimed |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | Compound Solutions Inc. (US) | 2023-07-13 | — | — | US | claimed |
| CN-116203057-A | Method for determining content of spermidine in spermidine hydrochloride by hydrogen nuclear magnetic quantitative analysis technology | 尚科生物医药（上海）有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-116064936-A | Primer probe, detection card and method for simultaneously detecting new coronavirus and influenza virus | 广州万孚生物技术股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115876904-A | Method for detecting purity of spermidine hydrochloride and related substances thereof | 尚科生物医药（上海）有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-111302953-B | Method for synthesizing spermidine hydrochloride | 南京康立瑞生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114588137-A | Application of triclosan in preparation of medicine for killing parasitic nematodes | 中国农业科学院兰州兽医研究所 | 2022-06-07 | — | — | CN | claimed |
| CN-112851447-A | Liquid fertilizer rich in nano silicon and spermidine, preparation method and application thereof in crop stress resistance | 广东海洋大学 | 2021-05-28 | — | — | CN | claimed |
| CN-102424825-A | Method for extracting total RNA from leaves and flower buds of filbert | UNIV BEIJING FORESTRY | 2012-04-25 | — | — | CN | claimed |
| CN-102121003-A | Method for extracting total rna | YANG JUN | 2011-07-13 | — | — | CN | claimed |
| CN-1829496-B | Use of spermine and/or spermidine against skin ageing in edible, pharmaceutical or cosmetic compositions | GIULIANI SPA | 2011-02-09 | — | — | CN | claimed |
| US-7803559-B1 | Protein aggregation regulators | THE REGENTS OF THE UNIVERSITY OF CA (US) | 2010-09-28 | — | — | US | claimed |
| EP-1926466-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2008-06-04 | — | — | EP | claimed |
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2007-11-29 | — | — | US | claimed |
| US-20070213257-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND PEPTIDES | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-09-13 | — | — | US | claimed |
| WO-2007040598-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2007-04-12 | — | — | WO | claimed |
| US-20070065390-A1 | Stable emulsion systems with high salt tolerance | RECKITT BENCKISER LLC | 2007-03-22 | — | — | US | claimed |
| CN-1829496-A | Use of spermine and/or spermidine against skin ageing in edible, pharmaceutical or cosmetic compositions | GIULIANI SPA (IT) | 2006-09-06 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276134-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND ORGANIC CATIONS | NSUN2, NSUN3, POLRMT | CA2 652/4885ESR1 2910/4885LMNA 750/4885 |
| US-20070213257-A1 | COMPOSITIONS AND METHODS FOR COMPLEXES OF NUCLEIC ACIDS AND PEPTIDES | NSUN2, NOP2, POLRMT | CA2 947/4885ESR1 3593/4885LMNA 299/4885 |
| US-20230219881-A1 | Synthesis of Spermidine, Spermine, and Free Bases Thereof | SRM, SMS, SMOX | CA2 2235/4885ESR1 4515/4885LMNA 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.